 Akcea Therapeutics, Inc. NASDAQ: AKCA, a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. NASDAQ: IONS, today announced that data from the Phase 2 study of AKCEA-APOCIII-LRx will be presented in a Late Breaking Clinical Trial Session at the upcoming ESC Congress 2020, the annual meeting of the European Society of Cardiology, which is expected to be the worlds largest online gathering of cardiovascular professionals, taking place August 29-September 1, 2020. 